Publications by authors named "D M Skovronsky"
Article Synopsis
- The study aimed to evaluate the effectiveness and side effects of donanemab, an antibody targeting amyloid plaques in the brains of Alzheimer's patients, as current treatment options are limited.
- The research involved a large-scale, 18-month clinical trial with 1736 participants diagnosed with early symptomatic Alzheimer disease, conducted across 277 medical centers in 8 countries from June 2020 to April 2023.
- Results showed that out of 24 assessed outcomes, 23 indicated significant improvement, with the donanemab group demonstrating a notable decrease in cognitive impairment compared to the placebo group over the 76-week period.
Background: Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment.
Methods: This Phase 3 portion of the BLAZE-1 trial characterized the effect of bamlanivimab with etesevimab on overall patient clinical status and virologic outcomes in ambulatory patients ≥12 years old, with mild-to-moderate coronavirus disease 2019 (COVID-19), and ≥1 risk factor for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab and etesevimab together (700/1400 mg) or placebo were infused intravenously within 3 days of patients' first positive COVID-19 test.
Background: Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications.
Methods: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, a cohort of ambulatory patients with mild or moderate Covid-19 who were at high risk for progression to severe disease to receive a single intravenous infusion of either a neutralizing monoclonal-antibody combination agent (2800 mg of bamlanivimab and 2800 mg of etesevimab, administered together) or placebo within 3 days after a laboratory diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Importance: Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection from SARS-CoV-2 infection and COVID-19.
Objective: To determine the effect of bamlanivimab on the incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities.
Article Synopsis
- Donanemab is an antibody designed to target amyloid-β (Aβ) peptide deposits, which are characteristic of Alzheimer's disease, and is being tested for early-stage treatment.
- A phase 2 trial involved 257 patients with early symptomatic Alzheimer's; they received either donanemab or a placebo for up to 72 weeks, with cognitive changes assessed primarily via the Integrated Alzheimer's Disease Rating Scale (iADRS).
- Results showed that donanemab had a slightly better effect on cognitive decline compared to placebo, with some reduction in amyloid levels, but no significant differences in most secondary cognitive measures and some cases of asymptomatic brain swelling were reported.